Collectively, these findings highlight the importance of metabolic and immune pathways in the pathogenesis of colorectal cancer and suggest that BET1L and OAS1 could serve as potential biomarkers or therapeutic targets. The gene discussed is BET1L; the disease is colorectal cancer.